Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis

Lugeng He, MDa, Hui Fang, PhDc,d, Chao Chen, PhDa, Yanqi Wu, PhDc,d, Yuyong Wang, PhDa, Hongwei Ge, PhDa, Lili Wang, PhDd, Yuehua Wan,d,c,∗ Huadong He, PhDa,b

Abstract
Background: In recent years, metastatic castration-resistant prostate cancer (MCRPC) and studies related to MCRPC have drawn global attention. The main objective of this bibliometric study was to provide an overview of MCRPC, explore clusters and trends in research and investigate the future direction of MCRPC research.

Methods: A total of 4089 publications published between 1979 and 2018 were retrieved from the Web of Science (WoS) Core Collection database. Different aspects of MCRPC research, including the countries/territories, institutions, journals, authors, research areas, funding agencies and author keywords, were analyzed.

Results: The number of annual MCRPC publications increased rapidly after 2010. American researchers played a vital role in this increase, as they published the most publications. The most productive institution was Memorial Sloan Kettering Cancer Center. Developing countries, especially the USA, were the leading nations for MCRPC research because of their abundant funding and frequent international collaborations. Therapy was one of the most vital aspects of MCRPC research. Therapies targeting PSMA (prostate-specific membrane antigen)-based radioligand therapy (RLT) would be the next focus of MCRPC research.

Conclusions: Developed countries, especially the USA, were the leading nations for MCRPC research because of their abundant funding and frequent international collaborations. Therapy was one of the most vital aspects of MCRPC research. Therapies targeting DNA repair or the androgen receptor (AR) signaling pathway and new therapies especially prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) would be the next focus of MCRPC research.

Abbreviations: AA/P = abiraterone acetate plus prednisone, ACCP = average citations per paper, AR = androgen receptor, CTG = circulating tumor cells, DDA = Derwent Data Analyzer, FDA = Food and Drug Administration, MCRPC = metastatic castration-resistant prostate cancer, nCC = number of cooperative countries or regions, OS = overall survival, PSMA = prostate-specific membrane antigen, RLT = radioligand therapy, SP = Share of publications, TC = total citations, TP = total paper, TPR% = the percentage of articles of journals in total publications, WoS = Web of Science.

Keywords: bibliometric analysis, bone metastases, drug resistance, metastatic castration-resistant prostate cancer (MCRPC), prostate-specific membrane antigen (PSMA), therapy

1. Introduction

Prostate cancer (PCa) is one of the most prevalent malignancies in the world[1–3] and the third most common cause of male cancer-related death in the United States of America (USA).[4] The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).[4–5] Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years.[6–7] CRPC was previously named “hormone-refractory prostate cancer” and
“androgen-independent prostate cancer”. Therefore, however, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation. Thus, “hormone-refractory prostate cancer” and “androgen-independent prostate cancer” were replaced by the term “castration-resistant prostate cancer (CRPC)”. Although metastatic castration-resistant prostate cancer (mCRPC) patients currently benefit from a wealth of effective treatment options, mCRPC remains incurable, and the prognosis of these patients is quite poor. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with mCRPC, this survival is reduced to 9–13 months.

Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for mCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for mCRPC treatment. Abiraterone and enzalutamide represent significant breakthroughs in the treatment of mCRPC and bestow significant survival benefits. Spindle cell-T, a novel active cellular immunotherapy, can prolong the overall survival (OS) of men with mCRPC. Radium-223 (Ra 223) dichloride targets bone metastases with high-energy, short-range a-particles, improves OS, and is a good treatment option for patients with CRPC and symptomatic bone metastases. Denosumab, a human anti-RANKL monoclonal antibody, can delay bone metastasis in men with PCa. According to recent guidelines, the first-line treatments for mCRPC include abiraterone acetate plus prednisone (AA/P), enzalutamide, radium 223, docetaxel, and sipuleucel-T. Cabazitaxel, AA/P, enzalutamide, and radium have been approved as second-line treatments for CRPC following docetaxel treatment. Although men with mCRPC benefit from all of these new therapies, a significant proportion of patients exhibit primary resistance to these agents, and virtually all patients develop secondary resistance. The resistance mechanisms of tumors to AR blocking agents, including AR protein overexpression, AR gene amplification, AR gene mutations, and AR variants (AR-Vs), are directly related to the activation of AR-dependent pathways and processes independent of the AR signaling pathway. The reported mechanisms of resistance to taxanes are related to several contributing factors, such as tubulin alterations, multidrug-resistance (MDR) kinesin overexpression, signaling pathways and cytokines related to epithelial-mesenchymal transition (EMT), ETS fusion gene family members, and AR splice variants (AR-SVs). Putative predictive biomarkers, including AR-SVs, homologous recombination (HR) repair defects including BRCA2 loss, mismatch repair (MMR) defects, and phosphatase and tensin homolog (PTEN) defects, would also benefit the treatment of the disease.

2. Method and data

This bibliometric study analyzed the papers related to “metastatic castration-resistant prostate cancer” obtained from the Science Citation Index-Expanded (SCI-E) that were published during the period from 1979 to 2018 (the year 1979 was chosen as a starting point when the first paper was published). The data were acquired through the Web of Science (WoS) Core Collection database by searching the “topic” field, which included the title, abstract, and keyword fields, on 4 November 2018. The search strategy for the WoS database was (TS=“castrat* resistant” or “hormone refractory” or “hormone independent” or “hormone resistant” or “hormone insensitive” or “androgen independent” or “androgen insensitive” or “androgen refractory” or “castration recurrent” or “androgen resistant” or “castration refractory”) and metastatic and (“prostat* Neoplasm” or “prostat* Tumor*” or “prostat* Cancer*” or “prostat* carcinoma*” or “prostat* adenocarcinoma*”) or (“mCRPC” or “metastatic CRPC” or “metastatic neuroendocrine prostate cancer” OR “metastatic NEPC”). The papers originating from England, Scotland, Northern Ireland, and Wales were classified as belonging to the United Kingdom (UK), while those from Macao, Taiwan, and Hong Kong were not grouped under the China heading.

A total of 6,304 publications, including 118 SCI-E highly cited articles and 4 SCI-E hot articles, matched the choice criteria listed above across 13 document types. The 13 document types were article (3,004), meeting abstract (1,883), review (785), editorial material (201), proceedings paper (123), letter (82), correction (29), news item (10), note (9), data paper (5), book chapter (4), retracted publication (3), and retraction (1). Of the 6,304 publications, a total of 6,124 (97.145%) were published in English. The other eight languages were German (83; 1.317%), French (65; 1.031%), Spanish (25; 0.397%), Hungarian (3; 0.048%), Korean (1; 0.016%), Polish (1; 0.016%), Welsh (1; 0.016%), and Turkish (1; 0.04%). Thus, English was the predominant language of the academic publications on mCRPC.
research. Only articles and reviews were further analyzed because they not only comprised the majority of the publications but also were peer-reviewed. Meeting abstracts were not evaluated because they tend to reflect organizational logistics rather than editorial decisions.[74] The impact factors (IFs) of the WoS journals were determined from the 2017 Journal Citation Reports (JCR). Derwent Data Analyzer (DDA) software was used to assess the data and analyze journals, keywords, and international cooperation.

3. Results and discussion

3.1. The performance of related publications and countries

Seventy-six countries contributed 6304 publications to the MCRPC research field between 1979 and 2018, indicating that MCRPC is a global health problem that attracts worldwide attention. During the first year, there was only one published study within the WoS, and annual publication numbers grew slowly in the first 20 years (Fig. 1). During the next 10 years, the number of annual publications increased from 66 (2000) to 187 (2009). In the last 9 years (2010–2018), the annual publication number has increased rapidly, rising from 189 (2010) to 606 (2018). Thus, MCRPC has attracted increasing attention and has become one of the hottest research fields in cancer research.

3.2. Cooperation of countries/territories

Publications on MCRPC between 1979 and 2018 came from 76 countries. The top 20 most productive countries/territories in the MCRPC research field are shown in Table 1. The USA headed the list, with a publication share of 35.96% and the highest h-index (155). The UK ranked second, followed by Canada, France, Italy and Germany. The Netherlands, mainland China, Japan, and Spain were ranked in positions 6–10. The remaining 20 most productive countries/territories were mostly in Europe. Economic development seemed to not only increase the incidence of PCa[75,76] but also contribute to high scientific and academic investments, as nearly all of the 20 most productive countries/territories were economically prosperous. In Western countries, the incidence of PCa was higher than that in developing countries. The first reason for this difference was that the men in Western countries had more access to medical care, including screening and early detection.[77] The second reason was that the incidence of PCa was related to environmental, dietary, and genetic factors.[78–80]

DDA software was used to draw a network diagram from a cooccurrence matrix.[81] Each node represented a different country, and node size corresponded to the number of publications. Similarly, the lines connecting the countries represented their cooperation, and the line thickness indicated the frequencies of that collaboration. The academic collaboration network of the top 20 most productive countries/territories is shown in Figure 2. The USA was the center of this collaboration network and the leader of MCRPC research in cooperation with the other 53 countries/territories. Asian countries/territories such...
as mainland China, Japan, South Korea, and Taiwan had smaller collaboration networks than European countries and North American countries, might explain why Asian countries/territories had smaller h-indexes, TCs, and ACCPs. This network might also suggest that collaborations benefit the number, impact, and quality of the papers.\[82\]

### 3.3. Institute contributions to publications

The top 20 most productive institutes from 1979 to 2018 are listed in Table 2: three of these institutes are based in the UK, two are in Canada, and the rest are in the USA. This distribution reiterated the predominance of the USA in the research field of MCRPC. As the most historical and largest private cancer center in the world,
Memorial Sloan Kettering Cancer Center contributed 208 publications, more than any other institution, accounting for 5.087% of the world’s publications in this field, and these publications were accompanied by 22,064 citations. The University of California San Francisco was second in productivity, with 181 publications and a total of 17,523 citations. The University of Washington and the University of Michigan ranked third and fourth, respectively. Regarding the h-index, Memorial Sloan Kettering Cancer Center also ranked first, followed by the University of Michigan and University of Washington. The institutions with high h-indices were mainly from the USA, the UK and Canada, indicating that these countries had outstanding academic institutions and capabilities in this field of MCRPC.

3.4. Contributions of leading authors

Many scientists from a wide range of origins have researched MCRPC and published their findings in the WoS. The top 15 authors in MCRPC research are listed in Table 3. The most prolific author on the topic was de Bono, JS, who published 132 scientific articles and had a total of 16,423 citations. In addition, the author with the highest number of citations and the most citations per article published was Scher, HI, who had 115 articles and 19,797 citations. In the top 15 authors, de Bono, JS was the only author from the UK; Fizazi, K was from France; Saad, F and Chi, KN were from Canada; Scher, HI and the other top 10 scientists were American. These institutions where these scientists worked were generally among the top 20 most productive institutions. For example, de Bono, JS worked at the Institute of Cancer Research, and Scher, HI worked at Memorial Sloan Kettering Cancer Center. In addition to these top scientists, there were more than 16,000 scientists in the world researching MCRPC.

3.5. Contributions in leading research areas and journals

A total of 4089 articles were published in the MCRPC research field, and these articles involved 52 research areas. The distribution of the top 20 research areas in MCRPC research is listed in Table 4. “Oncology” was undoubtedly the dominant research area, with 2120 articles, followed by “urology nephrology,” “pharmacology pharmacy,” “endocrinology metabolism,” “cell biology,” and “biochemistry molecular biology.” There were 2120 publications in the area of “oncology,” comprising 51.85% of the total publications, and “oncology” had the highest h-index (134). This analysis illustrated that research hotspots were correlated with the prevention, diagnosis, and treatment of cancer. “Pharmacology pharmacy” ranked third, indicating that therapy was an essential area of MCRPC research. All indicated the importance of treatments such as chemotherapy, new hormone therapy, immunotherapy, radiotherapy, and targeted therapy in the MCRPC research field.

A total of 4089 articles were published in 595 journals, with 257 journals publishing only one article and 111 journals publishing only two articles. There are 20 journals identified in Table 5, and their MCRPC publication numbers, total citations, average citations per item, h-indexes, and impact factors (impact factors were obtained from JCR 2017) are also listed. The journal Prostate headed the list with a total number of 184 publications, followed by the journal Clinical Cancer Research (153), the journal European Urology (123), and the journal Clinical Genitourinary Cancer (116). The sixth place journal Oncotarget was excluded from the WoS in 2017; thus, its IF was unknown.

A bubble chart was also used to show the trend in the publications. The trend of the top 20 productive journals by year is displayed in Figure 3. There were quite a few articles published in the top 20 productive journals from 1981 to 2000. During 2001–2010, the publications in these journals increased steadily, similar to the pattern for total publication numbers shown in Figure 1. Since 2010, the annual number of articles in most journals, such as Prostate, Clinical Cancer Research, European Urology, and Clinical Genitourinary Cancer, has increased rapidly, as shown in Figure 3. Annual papers of partial journals remained relatively steady, such as the journal Cancer Research, the journal Cancer, and the Journal of Clinical Oncology.

3.6. Contributions of funding agencies

Scientific productivity is related to research and development expenditures. The distribution of the top 20 most
productive funding agencies for MCRPC research is displayed in Table 6. The National Institutes of Health (NIH) topped the list with 809 funded articles and the highest h-index (111). The pharmaceutical company Johnson & Johnson ranked second with 166 funded articles. The Prostate Cancer Foundation (PCF) ranked third with 161 funded articles. Pfizer (157) and Astellas (155) followed the Department of Defense (DOD), which funded 161 articles. The National Natural Science Foundation of China (NNSFC) ranked 11th with 77 funded articles and an h-index of 15. Twelve of these 20 funding agencies were global pharmaceutical companies, and the remaining 8 were state-funded institutions or charitable foundations. The NIH was the world’s largest funder of biomedical research and invested approximately $30 billion per year in biomedical research.[89] The PCF was the world’s leading philanthropic organization funding and accelerating PCa research, and it raised more than $765 million and funded more than 2000 research programs at nearly 210 cancer centers and universities.[90] The NNSFC, the largest natural science foundation in China, invested nearly $1.1 billion in biomedical research in 2018.[91]

### Table 4

| Rank | Research area                          | TP  | TPR%   | TC    | h-index | ACCP  |
|------|----------------------------------------|-----|--------|-------|---------|-------|
| 1    | Oncology                               | 2120| 51.84% | 83120 | 134     | 39.21 |
| 2    | Urology Nephrology                     | 1158| 28.52% | 26221 | 72      | 22.64 |
| 3    | Pharmacology Pharmacy                  | 342 | 8.36%  | 4566  | 33      | 13.32 |
| 4    | Endocrinology Metabolism               | 297 | 7.26%  | 8621  | 49      | 29.03 |
| 5    | Cell Biology                           | 237 | 5.79%  | 7599  | 40      | 32.06 |
| 6    | Biochemistry Molecular Biology         | 210 | 5.13%  | 8180  | 45      | 38.95 |
| 7    | Radiology Nuclear Medicine Medical Imaging | 172 | 4.20%  | 3971  | 36      | 23.09 |
| 8    | Research Experimental Medicine         | 138 | 3.37%  | 5008  | 36      | 36.29 |
| 9    | Science Technology Other Topics        | 129 | 3.15%  | 9078  | 34      | 70.37 |
| 10   | General Internal Medicine              | 86  | 2.10%  | 21524 | 21      | 250.28|
| 11   | Biotechnology Applied Microbiology     | 75  | 1.83%  | 2054  | 21      | 27.39 |
| 12   | Pathology                              | 66  | 1.61%  | 3589  | 27      | 54.38 |
| 13   | Immunology                             | 64  | 1.56%  | 1581  | 21      | 24.7  |
| 14   | Genetics Heredity                     | 62  | 1.51%  | 2646  | 26      | 42.68 |
| 15   | Health Care Sciences Services          | 55  | 1.34%  | 577   | 12      | 10.49 |
| 16   | Chemistry                              | 40  | 0.97%  | 418   | 10      | 10.45 |
| 17   | Hematology                             | 35  | 0.85%  | 375   | 13      | 10.71 |
| 18   | Toxicology                             | 27  | 0.60%  | 255   | 11      | 9.44  |
| 19   | Geriatrics Gerontology                 | 20  | 0.49%  | 262   | 9       | 13.1  |
| 20   | Biophysics                             | 19  | 0.46%  | 580   | 13      | 30.53 |

ACCP = average citations per paper, TC = total citations, TP = total paper, TPR% = the percentage of share publications.

---

He et al. Medicine (2020) 99:15  Medicine

---

Figure 3. Bubble chart of the top 20 productive journals by year.
NIH and PCF, the NNSFC needs to expend more efforts to not only increase research sponsorship funds but also improve the quality of academic outputs.

The influence of commercial interests on medical science was worldwide and essential. For example, abiraterone acetate was first reported in the 1990s and until 2009, the rights for the commercialization of abiraterone acetate were held by Johnson & Johnson, which conducted ongoing clinical trials to expand the clinical uses of abiraterone acetate. With the efforts of Johnson & Johnson, abiraterone acetate became a standard treatment for CRPC and MCRPC. The commercialization of other drugs followed similar patterns. However, biomedical research funded by for-profit companies can be influenced in important ways. The sponsorship of drug or device studies by the manufacturing company led to more favorable efficacy results and conclusions than sponsorship by other sources. Even the professional medical associations (PMAs) playing an essential role in defining and advancing health care standards could be influenced by pharmaceutical and device companies. Sometimes irregularities at those companies, such as refusing to provide all the research data to the study team, reporting partial data as the primary outcome, incomplete reporting of some adverse events, or concealing some clinical trial data showing harm, were reported. In addition, the worst breach of trust was that clinical trial manuscripts authored by sponsor employees attributed first authorship to investigators who did not always disclose their industry-based financial support. This issue was also the reason that authors were required to detail their competing interests.

3.6.1. Analysis of keywords. Keyword analysis offers information on how authors conceptualize their own research, and keywords have been vital for monitoring the development of science. However, our keyword analysis also had a limitation; papers without author keywords were excluded from the analysis. Keywords appearing in the MCRPC articles from 1979 to 2018 were analyzed and ranked. The top 30 author keywords by year are displayed in Figure 4. Apart from the most frequently used searching keywords “prostate cancer” and “castration-resistant prostate cancer,” the other keywords that frequently appeared at the same time were “docetaxel” (330, ranking 3rd), “abiraterone” (321, ranking 4th), “castration-resistant” (321, ranking 5th), “metastatic castration-resistant prostate cancer” (275, ranking 6th), “metastasis” (274, ranking 7th), “chemotherapy” (263, ranking 8th), “androgen receptor” (ranking 9th) and “enzalutamide” (ranking 10th). Obviously, some author keywords were related to MCRPC therapy, such as “docetaxel,” “abiraterone,” and “cabazitamide.”

![Figure 4. Bubble chart of top 30 author keywords by year.](https://www.md-journal.com)
cabazitaxel are taxane chemotherapy agents. Abiraterone and enzalutamide are ADT agents. The articles related to "docetaxel," "abiraterone," "chemotherapy," "enzalutamide," "immunotherapy," "cabazitaxel," or "radium-223" sharply increased after 2010. This increase illustrated that the new therapies became topics of interest once they were approved by the US Food and Drug Administration (FDA); however, the increase in docetaxel publications did not match this trend since docetaxel was approved by the FDA in 2004.\[109\]

### Table 5

| Journal name                                      | TP   | TPR% | TC  | h-index | ACCP  | PCP% | IF        |
|--------------------------------------------------|------|------|-----|---------|-------|------|-----------|
| Prostate                                         | 184  | 4.500| 617 | 39      | 33.54 | 92.391| 3.347     |
| Clinical Cancer Research                         | 153  | 3.742| 12841| 61    | 83.93 | 96.732| 10.199    |
| European Urology                                 | 123  | 3.008| 5973 | 41    | 48.56 | 100.000| 17.581    |
| Clinical Genitourinary Cancer                    | 116  | 2.837| 942  | 18    | 8.12  | 79.310| 2.539     |
| BJU International                                | 96   | 2.348| 2103 | 26    | 21.91 | 95.833| 4.688     |
| Oncotarget                                       | 96   | 2.348| 1089 | 19    | 11.34 | 90.625|          |
| Cancer                                           | 92   | 2.250| 13922| 60    | 151.33| 96.739| 9.13      |
| Journal of Clinical Oncology                     | 90   | 2.201| 3974 | 33    | 44.16 | 97.778| 6.537     |
| Urologic Oncology Seminars And Original Investigations | 87   | 2.128| 12626| 56    | 145.13| 100.000| 26.36     |
| Journal of Urology                               | 82   | 2.005| 1167 | 20    | 14.23 | 80.488| 3.397     |
| Urology                                          | 80   | 1.956| 3248 | 31    | 40.6  | 96.250| 5.581     |
| Annals of Oncology                               | 66   | 1.614| 2442 | 26    | 37    | 98.485| 2.3       |
| Prostate And Prostatic Diseases                  | 64   | 1.565| 3156 | 33    | 49.31 | 98.438| 13.93     |
| Prostate Cancer And Prostatic Diseases           | 64   | 1.565| 1409 | 20    | 22.02 | 96.875| 2.766     |
| Prostate Cancer Foundation                       | 61   | 1.492| 861  | 18    | 14.11 | 91.803| 4.099     |
| Anticancer Research                              | 52   | 1.272| 578  | 14    | 11.12 | 92.308| 1.665     |
| British Journal of Cancer                        | 49   | 1.198| 1478 | 23    | 30.16 | 95.918| 5.022     |
| European Journal of Cancer                       | 49   | 1.198| 1430 | 22    | 29.18 | 100.000| 7.191     |
| International Journal of Cancer                  | 40   | 0.978| 1359 | 22    | 33.98 | 97.500| 7.36      |
| European Journal of Nuclear Medicine And Molecular Imaging | 38   | 0.929| 927  | 17    | 24.39 | 100.000| 7.704     |

TP = total paper, TPR% = the percentage of articles of journals in total publications.

### Table 6

| Rank | Funding agencies                             | TP   | TC    | ACCP | h-index | Country   |
|------|----------------------------------------------|------|-------|------|---------|-----------|
| 1    | National Institutes of Health                | 809  | 49261 | 60.89| 111     | USA       |
| 2    | Johnson & Johnson                            | 166  | 11194 | 67.43| 35      | USA       |
| 3    | Prostate Cancer Foundation                   | 161  | 13497 | 83.83| 49      | USA       |
| 4    | Department of Defense                        | 161  | 9151  | 56.84| 42      | USA       |
| 5    | Pfizer                                       | 157  | 10389 | 66.17| 35      | USA       |
| 6    | Astellas                                     | 155  | 9361  | 60.39| 32      | Japan     |
| 7    | Sanofi Aventis                               | 119  | 10524 | 88.44| 35      | France    |
| 8    | Sanofi                                       | 107  | 2847  | 26.61| 23      | France    |
| 9    | Bayer                                        | 89   | 6802  | 77.71| 21      | Germany   |
| 10   | Novartis                                     | 83   | 7726  | 93.08| 29      | Switzerland|
| 11   | National Natural Science Foundation of China | 77   | 680   | 8.83 | 15      | China     |
| 12   | Cancer Research UK                           | 74   | 4162  | 56.24| 31      | UK        |
| 13   | Dendreon                                     | 71   | 9648  | 135.89| 26      | USA       |
| 14   | Bristol Myers Squibb                         | 65   | 9184  | 141.29| 29      | USA       |
| 15   | Astrazeneca                                  | 47   | 7293  | 155.17| 25      | UK and Sweden|
| 16   | National Institute For Health Research       | 45   | 5497  | 122.16| 26      | UK        |
| 17   | Medical Research Council                     | 41   | 5114  | 124.73| 25      | UK        |
| 18   | Amgen                                        | 41   | 6544  | 159.61| 20      | USA       |
| 19   | American Cancer Society                      | 40   | 3105  | 77.63| 22      | USA       |
| 20   | Takeda                                       | 34   | 4153  | 122.15| 15      | Japan     |

ACCP = average citations per paper, IF = impact factor, TC = total citations, TP = total paper, TPR% = the percentage of articles of journals in total publications.

3.6.2. Research trends and future hotspots. Given the results in Figure 4, new therapies appear to become areas of interest once they are reported. Therapies that target critical cellular mechanisms of drug resistance are considered to be the most promising approaches for MCRPC therapy.\[111\] Many new drugs (such as darolutamide\[110\] and apalutamide\[111\]) targeting androgen signaling are being tested in clinical trials and will hopefully be effective in abiraterone- or enzalutamide-resistant patients. Emergence Indicators in DDA8 software have been proved useful to spotlight “hot” research topics within the domain.\[112,113\] The scores are calculated from four criteria—Novelty, Persistence, Growth and Community—\[114\] and represent the accuracy of predicting the research trends in the next few years. The emergence scores of 15 author keywords are displayed in Table 7. “Prostate-specific membrane antigen (PSMA)” achieved the second highest emergence score of 10.504, followed
by “Radiotherapy” (5.862), “Radium-223” (5.04), “Liquid biopsy” (4.907) and “Bone metastases” (4.613).

PSMA is frequently overexpressed and strongly upregulated in PCa, making PSMA-based RLT a promising treatment for MCRPC. RLT with [Lu-177] Lu-PSMA-617 (Lu-PSMA) was first reported in 2015 and attracted the most scholarly attention due to its low toxicity profile and respectable response rates. Liquid biopsy is widely applied to cancer research and will play a vital role in predicting the therapeutic efficiency or resistance to therapy. “DNA repair” ranked 8th with an emergence score of 3.729. DNA repair defects might present another promising treatment opportunity for patients with MCRPC. treatments that might include PARP inhibition and platinum chemotherapy. Research on bone metastasis has also attracted considerable attention, and radium 223 is the most promising treatment for patients with bone metastases. AR and the AR signaling pathway remain the principal drivers of the development and progression of MCRPC, making AR and its signaling pathway the main targets of principal therapeutic approaches. The drug resistance or cross-resistance of therapies might affect drug sequence choices in MCRPC, making drug sequences a promising hotspot in the future.

### 3.7. An Analysis of the most cited papers

Although multiple indicators were used to evaluate the impact of scientific publications, citation counts are still an important measurement of influence in this research field. The top 20 most cited publications in the MCRPC research field during 1981–2018 are presented in Table 7. The most highly cited paper was “Spinal-Cord Immunotherapy for Castration-Resistant Prostate Cancer.” This article was published in the New England Journal of Medicine in 2010 by Kantoff, PW and headed the lists of total citations (2715) and annual citations (339.36). “Abiraterone and Increased Survival in Metastatic Prostate Cancer,” authored by de Bono, JS et al, took second place, with 2045 total citations and 292.14 annual citations. “Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy,” authored by Scher, HI et al, ranked third with 1837 total citations and 309.5 annual citations.

Among these top 20 papers, 7 were published in the New England Journal of Medicine; 2 were published in Lancet; 2 were published in the Journal of Clinical Oncology; 2 were published in European Urology; 2 were published in Clinical Cancer Research; and Nature, Science, Cell, Lancet Oncology and Cancer Research each published 1 of the top articles. Eight papers had only American authors, and the remaining 12 papers had authors from more than 2 countries, meaning they were papers that resulted from international cooperation. Fifteen of the top scientists, such as de Bono, JS and Scher, HI, participated in 14 papers in a cooperative manner. This finding illustrated that the top scientists played a key role in the development of the entire field and that collaborations benefited the number, impact and quality of papers. Most of the top 20 papers were related to therapies for MCRPC, demonstrating that therapy was the most critical area of MCRPC research.

### 4. Conclusions

In this paper, a bibliometric analysis was performed to evaluate the trends in MCRPC research during 1979–2018. The results showed that the publications in MCRPC research increased significantly after 2010, possibly due to new therapies, such as abiraterone and enzalutamide. The findings illustrated that the USA dominated the MCRPC research in the areas of total publications, top institutions, top scientists and most cited papers. Some information could be obtained from this study:

1. MCRPC has attracted increasing attention and has become a worldwide health issue.
2. Compared with the USA, Asian countries, especially mainland China, are required to exert more effort in the areas of research funding and international collaboration to improve the impact and quality of their publications.
3. When facing drug resistance, combined therapies might improve quality of life and extend survival. Understanding the cellular mechanisms would help the development of new drugs that overcome existing resistance. Liquid biopsy will play a vital role in predicting the therapeutic efficiency or resistance to therapy.
4. Therapies that target critical cellular mechanisms of drug resistance, especially PSMA-based RLT and new therapies...
Table 8
The top 20 most cited publications in MCRPC research field during 1979-2018.

| No | Authors | Title | Total citations | Citation/year | Journal/IF2017 | Publication year | Country (authors from) |
|----|---------|-------|----------------|--------------|----------------|----------------|-----------------------|
| 1  | Kantoff, PW; Higano, CS; et al | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. | 2715 | 339.36 | New England Journal of Medicine | 2010 | USA |
| 2  | de Bono, JS; Rizzi, K; Chi, KN; Saad, F; Ryan, CJ; Scher, HI; et al | Abiraterone and Increased Survival in Metastatic Prostate Cancer. | 2045 | 292.14 | New England Journal of Medicine | 2011 | UK, USA, France, Canada, Australia, Italy |
| 3  | Scher, H; Rizzi, K; Saad, F; Chi, KN; Armstrong, AJ; de Bono, JS; et al | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. | 1857 | 309.5 | New England Journal of Medicine | 2012 | USA, France, Canada, Italy, Germany, The Netherlands, UK, Australia |
| 4  | de Bono, JS; Santoro, C; et al | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | 1615 | 201.86 | Lancet | 2010 | UK, USA, France, Turkey, Denmark, Belgium, Czech Republic, Hungary |
| 5  | Topalian, SL; Brahmer, JR; et al | Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates | 1368 | 171 | Journal Of Clinical Oncology | 2010 | USA |
| 6  | Ryan, CJ; de Bono, JS; Rizzi, K; Smad, DJ; Saad, F; Higano, CS; Scher, HI; et al | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy | 1237 | 247.4 | New England Journal of Medicine | 2013 | USA, UK, Australia, France, Spain, The Netherlands, Canada, Belgium, Germany, Greece |
| 7  | Scher, HI; Sartor, O; et al | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | 1099 | 109.9 | Clinical Cancer Research | 2008 | USA |
| 8  | Parker, C; Santor, O; et al | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer | 1099 | 219.8 | New England Journal of Medicine | 2013 | UK, Sweden, Norway, Czech Republic, Poland, Slovakia, Germany, Brazil, USA |
| 9  | Jung, ME; Tan, C; Higano, CS; Ber, TM; Scher, HI; et al | Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer | 1103 | 122.56 | Science | 2009 | USA |
| 10 | Pianta, KJ; Grasso, CS; et al | The mutational landscape of lethal castration-resistant prostate cancer | 979 | 163.17 | Nature | 2012 | USA |
| 11 | Beer, TM; Armstrong, AJ; Higano, CS; de Bono, JS; Rizzi, K; Saad, F; Scher, HI; et al | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy | 941 | 235.25 | New England Journal of Medicine | 2014 | USA, France, Italy, Denmark, Spain, UK, Australia, Canada, South Korea, Japan, Germany, Belgium |
| 12 | Antonarakis, ES; Carducci, MA; et al | AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. | 928 | 232 | New England Journal of Medicine | 2014 | USA |
| 13 | Taube, JM; et al | Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy | 907 | 226.75 | Clinical Cancer Research | 2014 | USA |
| 14 | Heidenreich, A*; et al | EU guidelines on prostate cancer | 870 | 87 | European Urology | 2006 | Germany, Sweden, France, Belgium, Russia, Switzerland, Italy |
| 15 | Nelson, PS; Montgomery, RB; Higano, CS; et al | Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth | 797 | 79.7 | Cancer Research | 2008 | USA |
| 16 | Sawyer, CL; Robinson, D; Scher, H; Kantoff, PW; de Bono, JS; et al | Integrative Clinical Genomics of Advanced Prostate Cancer | 772 | 257.33 | Cell | 2015 | USA, UK, Italy |
| 17 | Scher, H; Beer, TM; Higano, CS; et al | Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study | 667 | 83.38 | Lancet | 2010 | USA |
| 18 | Heidenreich, A*; et al | EU Guidelines on Prostate Cancer: Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer | 673 | 168.25 | European Urology | 2014 | Germany, Spain, Sweden, France, Belgium, The Netherlands, UK, Russia, Italy |
| 19 | Tannock, IF; Berthold, DB; et al | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study | 662 | 66.2 | Journal Of Clinical Oncology | 2008 | Canada, The Netherlands, USA |
| 20 | Rizzi, K; Scher, H; CN; Saad, F; de Bono, JS; et al | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | 622 | 103.67 | Lancet Oncology | 2012 | France, USA, Canada, Scotland, Canada, Australia, Italy |

1: first author; *: corresponding author; Total Citation/Year: Total Citation/(2018-Publication Year).
targeting DNA repair or the AR signing pathway, could be the next hotspot.

5) Research on bone metastasis has also attracted considerable attention, and radium 223 is the most promising treatment for patients with bone metastases. This study will help researchers understand the global overview of MCRPC, find potential collaborators in Western countries and grasp the promising attractive areas of MCRPC research.

Author contributions
Conceptualization: Yuehua Wan, Huadong He.
Data curation: Hui Fang.
Formal analysis: Hui Fang, Yuehua Wan, Yaqi Wu.
Funding acquisition: Chao Chen.
Investigation: Lugeng He, Chao Chen, Yuyong Wang, Hongwei Ge, Lili Wang.
Methodology: Huadong He.
Project administration: Yuehua Wan, Huadong He.
Resources: Lili Wang.
Visualization: Hongwei Ge.
Writing – review & editing: Yuehua Wan.
Lugeng He: 0000-0001-5059-9005.

References
[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. Ca-a Cancer Journal for Clinicians 2018;68:7–30. https://doi.org/10.3322/cac.21442.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. https://doi.org/10.3322/caac.21338.
[3] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403. https://doi.org/10.1016/j.ejca.2012.12.027.
[4] Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80. https://doi.org/10.1016/j.eururo.2007.09.002.
[5] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Local Treatment with Curative Intention. Eur Urol 2017;71:618–29. https://doi.org/10.1016/j.eururo.2016.08.003.
[6] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2014;65:467–79. https://doi.org/10.1016/j.eururo.2013.11.002.
[7] Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71:630–42. https://doi.org/10.1016/j.eururo.2016.08.002.
[8] Ahmad K. New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol 2004;5:706https://doi.org/10.1016/S1470-2045(04)01641-9.
[9] Perrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005;65:8–12. https://doi.org/10.1016/j.urology.2005.04.020.
[10] Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54. https://doi.org/10.1158/0008-5472.CAN-08-0249.
[11] Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Pract 2011;8:65:1180–92. https://doi.org/10.1038/jncl.2011.136.
[12] Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180–92. https://doi.org/10.1111/j.1742-1241.2011.02799.x.
[90] The Prostate Cancer Foundation Announces Recipients of the 2018 PCF Young Investigator Awards. 2018.

[91] China CoNNSFo. The statistics of projects funded by National Natural Science Foundation of China in 2018. http://www.nscf.gov.cn/publish/portal/1055/2018.

[92] DeAngelis CD. The influence of money on medical science. JAMA 2000;283:956–6. https://doi.org/10.1001/jama.283.8.956.

[93] Moses H, Dorsey ER, Mathemus DHM, et al. Financial anatomy of biomedical research. Jama-J Am Med Assoc 2005;294:1333–42. https://doi.org/10.1001/jama.2004.11333.

[94] Potter GA, Hardcastle IR, Jarman M. A convenient, large-scale synthesis of abiraterone acetate [3 beta-acetoxy-17-(3-pyridyl)androsta-5,16-diene], a potential new drug for the treatment of prostate cancer. Org Preced Int 1997;29:123–8. https://doi.org/10.1080/0030494970935175.

[95] Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research - A systematic review. Jama-J Am Med Assoc 2003;289:454–65. https://doi.org/10.1001/jama.289.4.454.

[96] Lexchin J, Berou LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ-British Medical Journal 2003;326:1167–70. https://doi.org/10.1136/bmj.326.7400.1167.

[97] Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome and quality: systematic review. Cochrane Database Syst Rev 2017;https://doi.org/10.1002/14651858.MR000033.pub2.

[98] Flacco ME, Manzoli L, Bocca S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. Clin Epidemiol 2015;6:811–20. https://doi.org/10.1016/j.jclinep.2014.12.016.

[99] Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional Medical Associations and Their Relationships With Industry A Proposal for Controlling Conflict of Interest. Jama-J Am Med Assoc 2009;301:1367–72. https://doi.org/10.1001/jama.2009.407.

[100] Kahn JO, Cheng DW, Mayer K, et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10^6/L CD4 cell counts - A randomized controlled trial. Jama-J Am Med Assoc 2000;284:2193–202. https://doi.org/10.1001/jama.284.17.2193.

[101] Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial. Jama-J Am Med Assoc 2000;284:1247–55. https:// doi.org/10.1001/jama.284.17.1247.

[102] Bombardier C, Laine L, Resin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–8. https://doi.org/10.1056/NEJM000112343120130.

[103] Corman GD, Morrissey S, Drazen JM. Expression of concern reafirmed. N Engl J Med 2006;354:1193–293. https://doi.org/10.1056/NEJMoa060504.

[104] Gibson L, GlaxoSmithKline to publish clinical trials after US lawsuit. Brit Med J 2004;328:1513–431. https://doi.org/10.1136/bmj.328.7455.1513-a.

[105] Ross JS, Hill KP, Egilman DS, et al. Guest authorship and ghostwriting in publications related to rofecoxib - A case study of industry documents from rofecoxib litigation. Jama-J Am Med Assoc 2008;299:1800–12. https://doi.org/10.1001/jama.299.15.1800.

[106] Chen K, Yao Q, Sun J, et al. International publication trends and collaboration performance of China in healthcare science and services research. Isr J Health Policy Res 2016;5:https://doi.org/10.1186/s13584-016-0061-z.

[107] Wu YQ, Wan YH, Zhang FZ. Characteristics and Trends of C-H Activation Research: A Review of Literature. Curr Org Synth 2018;15:781–92. https://doi.org/10.2174/1570719415666180426115417.

[108] Hao G, Fag F, Chen J, et al. Soft Robotics: Academic Insights and Perspectives Through Bibliometric Analysis. Soft Robot 2018;5:229–41. https://doi.org/10.1089/soro.2017.0135.

[109] Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.

[110] Shore ND. Darolutam (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 2017;18:945–52. https://doi.org/10.1080/14656566.2017.1329820.
Rathkopf DE, Antonarakis ES, Shore ND, et al. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res 2017;23:3544–51. https://doi.org/10.1158/1078-0432.CCR-16-2509.

Porter AL, Garner J, Newman NC, et al. National nanotechnology research prominence. Technol Anal Strateg 2019;31:25–39. https://doi.org/10.1080/09537325.2018.1480013.

Carley SF, Newman NC, Porter AL, et al. An indicator of technical emergence. Scientometrics 2018;115:35–49. https://doi.org/10.1007/s11192-018-2654-5.

Garner J, Carley S, Porter AL, et al. Technological Emergence Indicators Using Emergence Scoring. Portl Int Conf Manag 2017.

Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014;41:1280–92. https://doi.org/10.1007/s00259-014-2713-y.

Tagawa ST, Milowsky MI, Morris M, et al. Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2013;19:5182–91. https://doi.org/10.1186/1078-0432.ccr-13-0231.

Weinman M, Schottelius M, Simecek J, et al. Ga-68- and Lu-177-Labeled PSA M&CT: Optimization of a PSA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550.

Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-225-PSMA-617: Dosimetry Estimate and Empirc Dose Finding. J Nucl Med 2017;58:1624–31. https://doi.org/10.2967/jnumed.117.191395.

Yordanova A, Becker A, Eppard E, et al. The impact of repeated cycles of radioligand therapy using [Lu-177]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:1473–9. https://doi.org/10.1007/s00259-017-3681-9.

Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German Multicenter Study Investigating Lu-177-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194.

Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223–38. https://doi.org/10.1038/nrc.2017.7.

Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531–48. https://doi.org/10.1038/nrclinonc.2017.14.

Annala M, Vandraekhegh G, Khalaf D, et al. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov 2018;8:444–57. https://doi.org/10.1158/2326-066X.CD-17-0937.

Mateo J, Boysen G, Barbieri CE, et al. DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol 2017;71:417–25. https://doi.org/10.1016/j.euro.2016.08.037.

Cheng HH, Pritchard CC, Boyd T, et al. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;69:992–5. https://doi.org/10.1016/j.euro.2015.11.022.

Giacinti SPG, Roberto M, Macrini S, et al. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. Anticancer Res 2018;38:6029-6039. https://doi.org/10.21873/anticancerres.12953.

van Soest RJ, van Rossum ME, de Morree ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013;49:3821–30. https://doi.org/10.1016/j.ejca.2013.09.026.